Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF23 | Q9GZV9 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | GALR1 | P47211 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958644 | 0.81 | PTGS2 (0.50) | FGF23SLC6A3PTGS2ALDH1A1MAPK1 | |
| SCHEMBL1700335 | 0.77 | SLC6A3 (0.46) | FGF23SLC6A3PTGS2LMNAALDH1A1 | |
| SCHEMBL17460574 | 0.77 | PTGS2 (0.47) | FGF23SLC6A3PTGS2ALDH1A1MAPK1 | |
| SCHEMBL16439215 | 0.77 | MAPK14 (0.47) | FGF23SLC6A3PTGS2LMNAALDH1A1 | |
| SCHEMBL16439209 | 0.76 | FGF23 (0.55) | FGF23SLC6A3PTGS2LMNAALDH1A1 | |
| SCHEMBL1956409 | 0.76 | SLC6A3 (0.47) | FGF23SLC6A3PTGS2LMNAALDH1A1 | |
| SCHEMBL1957401 | 0.76 | SLC6A3 (0.47) | FGF23SLC6A3PTGS2LMNAALDH1A1 | |
| SCHEMBL1957404 | 0.76 | SLC6A3 (0.47) | FGF23SLC6A3PTGS2LMNAALDH1A1 | |
| SCHEMBL3378277 | 0.74 | FGF23 (0.53) | FGF23SLC6A3PTGS2ALDH1A1 | |
| SCHEMBL21855095 | 0.74 | CYP2A6 (0.44) | PTGS2ALDH1A1MAPK1PTGS1GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318767-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | SCHERING CORPORATION | 2012-04-12 | — | — | US | disclosed |
| US-8106070-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | ALBANY MOLECULAR RESEARCH, INC. | 2010-01-07 | — | — | US | disclosed |
| EP-2083822-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051404-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | BRS3, GPR119, GIPR | FGF23 1859/4885SLC6A3 395/4885PTGS2 2214/4885 |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | FGF23 1859/4885SLC6A3 395/4885PTGS2 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.